Mayflower Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Mayflower Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,485	Closed	-$225K	–	371
2023 Q1	$225K	Hold	13,485	–	–	0.03%	310
2022 Q4	$127K	Hold	13,485	–	–	0.02%	331
2022 Q3	$37K	Hold	13,485	–	–	0.01%	320
2022 Q2	$39K	Hold	13,485	–	–	0.01%	317
2022 Q1	$40K	Hold	13,485	–	–	0.01%	347
2021 Q4	$62K	Hold	13,485	–	–	0.01%	334
2021 Q3	$79K	Sell	13,485 -500	-4%	-$3.09K	0.01%	325
2021 Q2	$84K	Sell	13,985 -393	-3%	-$2.33K	0.01%	310
2021 Q1	$91K	Sell	14,378 -1,400	-9%	-$9.85K	0.01%	288
2020 Q4	$89K	Buy	+15,778	New	+$95.6K	0.02%	272

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Mayflower Financial Advisors's VKTX Position: Q2 2023 in Review

Mayflower Financial Advisors sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 13,485 shares — an estimated $225K sold.

Mayflower Financial Advisors first reported a position in VKTX in Q4 2020 and held it in 10 quarters. The position peaked at $225K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

Mayflower Financial Advisors reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
Mayflower Financial Advisors sold 13,485 Viking Therapeutics shares in Q2 2023, an estimated $225K.
Mayflower Financial Advisors first reported a position in Viking Therapeutics in Q4 2020 and held it in 10 quarters.
Mayflower Financial Advisors's Viking Therapeutics position peaked at $225K in Q1 2023.
193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Mayflower Financial Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.